Blog Posts
Quick filters:
Found 1 results for "2026 Outlook"
My 2026 Watchlist: 3 Asymmetric Trades for the M&A Supercycle
Wed, Dec 17, 2025
Big Pharma faces a $200B revenue hole in 2026. Here are the 3 cash-rich, commercial-stage stocks I'm tracking to play the coming M&A wave.
